Replies to post #95404 on Biotech Values

[ghmm]

GENZ/BMRN:

I didn't hear the analysts day presentation but I think a good move for BMRN would be to try to buy out Aldurazyme (on the cheap of course). The partnership hasn't been the greatest (uptake stinks) and its tiny for Genzyme in the scheme of things but would be a nice fit for BMRN to add to their sales force. This would be a lot better deal then some early stage oncology program IMO.

[Biowatch]

Genzyme ramps up stock repurchase

Genzyme Corp. (Nasdaq: GENZ) said Friday that Goldman, Sachs & Co. will repurchase $1 billion of Genzyme common stock "under an accelerated stock repurchase program."

Funding comes from a recent debt offering, Genzyme said. The purchase is part of an overall plan, announced in May, to buy back $2 billion of stock...

http://boston.bizjournals.com/boston/stories/2010/06/14/daily46.html?ana=yfcpc